J
Jan H.M. Schellens
Researcher at Utrecht University
Publications - 931
Citations - 51317
Jan H.M. Schellens is an academic researcher from Utrecht University. The author has contributed to research in topics: Pharmacokinetics & Population. The author has an hindex of 98, co-authored 921 publications receiving 44992 citations. Previous affiliations of Jan H.M. Schellens include Rotterdam University of Applied Sciences & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C.C. Fong,D. S. Boss,Timothy A. Yap,Andrew Tutt,Peijun Wu,Marja Mergui-Roelvink,Peter S. Mortimer,Helen Swaisland,Alan Lau,Mark J. O'Connor,Alan Ashworth,James Carmichael,Stan B. Kaye,Jan H.M. Schellens,Jan H.M. Schellens,Johann S. de Bono +15 more
TL;DR: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCa2 mutation.
Journal Article
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Marc Maliepaard,George L. Scheffer,I. F. Faneyte,M A van Gastelen,Adriana C L M Pijnenborg,A.H. Schinkel,M.J. van de Vijver,R.J. Scheper,Jan H.M. Schellens +8 more
TL;DR: The apical localization in the epithelium of the small intestine and colon indicates a possible role of BCRP in the regulation of the uptake of p.o. delivered B CRP substrates by back-transport of substrate drugs entering from the gut lumen and is consistent with the hypothesis of a protective role ofBCRP for the fetus.
Journal ArticleDOI
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C.C. Fong,Timothy A. Yap,D. S. Boss,Craig P. Carden,Marja Mergui-Roelvink,Charlie Gourley,Jacques De Greve,Jan Lubinski,Susan Shanley,Christina Messiou,Roger A'Hern,Andrew Tutt,Alan Ashworth,John F. Stone,James Carmichael,Jan H.M. Schellens,Johann S. de Bono,Stan B. Kaye +17 more
TL;DR: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity, a significant association between the clinical benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups.
Journal ArticleDOI
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz,Axel Grothey,Rona Yaeger,Eric Van Cutsem,Jayesh Desai,Takayuki Yoshino,Harpreet Wasan,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik Tobias Arkenau,Pilar García-Alfonso,Per Pfeiffer,Sergey Orlov,Sara Lonardi,Elena Elez,Tae Won Kim,Jan H.M. Schellens,Christina Guo,Asha Krishnan,Jeroen Dekervel,Van Morris,Aitana Calvo Ferrándiz,Line Schmidt Tarpgaard,Michael Braun,Ashwin Gollerkeri,Christopher Hunt Keir,Kati Maharry,Michael D Pickard,Janna Christy-Bittel,Lisa Anderson,Victor Sandor,Josep Tabernero +34 more
TL;DR: A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation.
Journal ArticleDOI
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
Jeany M. Rademaker-Lakhai,Desiree H.J.G. van den Bongard,Dick Pluim,Jos H. Beijnen,Jan H.M. Schellens +4 more
TL;DR: The maximum-tolerated dose (MTD), profile of adverse events, and dose-limiting toxicity of NAMI-A in patients with solid tumors were determined and the ruthenium pharmacokinetic analysis revealed a linear relationship between dose and area under the concentration-time curve (AUC) of total and unbound rUThenium.